Widerøe T E, Dahl K J, Smeby L C, Balstad T, Cruischank-Flakne S, Følling I, Simondsen O, Ahlmen J, Jørstad S
Department of Nephrology and Endocrinology, University Hospital, Trondheim, Norway.
Nephron. 1996;74(2):283-90. doi: 10.1159/000189322.
Seven type I insulin-dependent diabetic patients on continuous ambulatory peritoneal dialysis treatment were selected for this study. Each patient participated in three different 6-hour 'single-dwell' studies on 3 consecutive days. A mean dose of 33 +/- 1.3 U Insulin Actrapid Human was given intraperitoneally each day. The procedures for intraperitoneal insulin administration were: (1) with 1,000 ml Ringer lactate; (2) with 1,000 ml 3.86% glucose-containing dialysate, and (3) into an empty peritoneal cavity. The calculation of the intraperitoneal volume was done with a single injection indicator dilution technique in which 100 kBq radioiodinated serum albumin (RISA) was added into the fluid prior to instillation. Free insulin and glucose were analyzed at 16 time intervals in blood and in dialysate during each dwell. After drainage the peritoneal cavity was rinsed with 1,000 ml Ringer lactate followed by two consecutive 5-hour exchanges with 2,000 ml glucose-containing dialysate. Recovery of insulin and RISA was measured in rinsing fluid and in sampled dialysate during the 6-hour dwell. The kinetic calculations made for insulin were disappearance rate (mU/min) from the peritoneal cavity, and appearance rate in circulating blood. After drainage and rinsing, 66.0 +/- 10 and 71.8 +/- 9.8% of the insulin instilled had disappeared after 6 h from the glucose fluid and from the Ringer solution respectively and did not differ significantly. However, the estimated disappearance rate from the peritoneal cavity was significantly higher in Ringer than in glucose from the time interval 120 to 360 min. A high and peak-shaped insulin concentration in the plasma was found following insulin injection into an empty peritoneal cavity, and was significantly higher than when insulin was dissolved in a 1,000-ml fluid volume. However, a higher blood concentration was also found when Ringer was instilled than when a hyperosmolal glucose solution was instilled. A high first-pass elimination in the liver is suggested. In conclusion, fluid volume and also the osmolality of the solution in the peritoneal cavity decreases the transport rate, but not the bioavailability of insulin given intraperitoneally. Both a high peak shape and a continuous insulin appearance in blood can be achieved. It is suggested that there is a high first-pass elimination of insulin during absorption from the peritoneal cavity. However, the values are uncertain and extended investigations must be done.
本研究选取了7例接受持续性非卧床腹膜透析治疗的I型胰岛素依赖型糖尿病患者。每位患者连续3天参与3项不同的6小时“单次留腹”研究。每天经腹腔给予平均剂量为33±1.3单位的人速秀霖胰岛素。腹腔内胰岛素给药的方法如下:(1) 与1000毫升乳酸林格液一起;(2) 与1000毫升含3.86%葡萄糖的透析液一起,以及(3) 注入空的腹腔。腹腔容积的计算采用单次注射指示剂稀释技术,即在灌注前向液体中加入100千贝克勒尔放射性碘标记血清白蛋白(RISA)。在每次留腹期间,于16个时间点分析血液和透析液中的游离胰岛素和葡萄糖。引流后,用1000毫升乳酸林格液冲洗腹腔,随后连续两次用2000毫升含葡萄糖的透析液进行5小时的交换。在6小时留腹期间,测定冲洗液和采集的透析液中胰岛素和RISA的回收率。对胰岛素进行的动力学计算包括腹腔内的消失率(毫单位/分钟)和循环血液中的出现率。引流和冲洗后,分别在葡萄糖液和林格液中,注入的胰岛素在6小时后有66.0±10%和71.8±9.8%消失,两者无显著差异。然而,在120至360分钟的时间间隔内,林格液中腹腔内胰岛素的估计消失率显著高于葡萄糖液中的。将胰岛素注入空腹腔后,血浆中出现高且呈峰值状的胰岛素浓度,且显著高于胰岛素溶解于1000毫升液体量时的浓度。然而,注入林格液时的血药浓度也高于注入高渗葡萄糖溶液时的。提示肝脏存在较高的首过消除。总之,腹腔内溶液的液体量以及渗透压会降低胰岛素的转运速率,但不会降低腹腔内给予胰岛素的生物利用度。可实现血液中胰岛素的高峰值形状和持续出现。提示腹腔吸收过程中胰岛素存在较高的首过消除。然而,这些数值尚不确定,必须进行进一步的研究。